MeSH term
Frequency | Condition_Probility | Acute Disease | 15 | 0.0 |
Adult | 285 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 2 | 2.0 |
Comparative Study | 148 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 2 | 2.0 |
Fetal Blood/transplantation | 2 | 2.0 |
Humans | 1091 | 0.0 |
Leukemia/*therapy | 2 | 1.0 |
Patient Selection | 2 | 1.0 |
Biological Markers/*blood | 2 | 1.0 |
Case-Control Studies | 13 | 0.0 |
Child | 56 | 0.0 |
Child, Preschool | 47 | 0.0 |
Cohort Studies | 4 | 0.0 |
Female | 371 | 0.0 |
Immunization | 13 | 3.0 |
Incidence | 4 | 0.0 |
Male | 343 | 0.0 |
Middle Aged | 233 | 0.0 |
Pedigree | 9 | 0.0 |
Probability | 2 | 0.0 |
Prognosis | 12 | 0.0 |
Reference Values | 29 | 0.0 |
Risk Assessment | 2 | 0.0 |
Severity of Illness Index | 7 | 0.0 |
Statistics, Nonparametric | 5 | 0.0 |
Aged | 114 | 0.0 |
Aged, 80 and over | 29 | 0.0 |
Immunohistochemistry | 71 | 0.0 |
Myelin Basic Proteins/metabolism | 37 | 67.0 |
Research Support, Non-U.S. Gov't | 839 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 361 | 0.0 |
Sex Characteristics | 3 | 0.0 |
Diagnosis, Differential | 7 | 0.0 |
Amino Acid Sequence | 236 | 1.0 |
Animals | 456 | 0.0 |
Cattle | 51 | 1.0 |
Chickens | 12 | 1.0 |
DNA, Complementary/chemistry | 3 | 1.0 |
Fishes | 2 | 2.0 |
Gene Expression Regulation, Developmental/*physiology | 4 | 3.0 |
Mice | 195 | 0.0 |
Molecular Sequence Data | 283 | 0.0 |
*Nerve Tissue Proteins | 3 | 0.0 |
Rats | 131 | 0.0 |
Sequence Homology, Amino Acid | 30 | 0.0 |
Zebrafish | 2 | 1.0 |
Blotting, Western | 43 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
*Membrane Proteins | 4 | 0.0 |
Myelin Basic Proteins/analysis | 22 | 81.0 |
Myelin P0 Protein/analysis | 2 | 66.0 |
Myelin Proteins/*analysis | 7 | 46.0 |
Myelin Sheath/*chemistry | 2 | 33.0 |
Proteolipids/analysis | 2 | 100.0 |
Rats, Wistar | 6 | 0.0 |
Autoimmune Diseases/immunology | 9 | 10.0 |
Encephalomyelitis, Autoimmune, Experimental/*immunology/pathology | 4 | 50.0 |
T-Lymphocytes/*immunology | 86 | 3.0 |
Adolescent | 96 | 0.0 |
Multiple Sclerosis/*immunology/therapy | 4 | 57.0 |
Myelin Basic Proteins/immunology | 66 | 75.0 |
Myelin-Associated Glycoprotein/immunology | 6 | 30.0 |
Receptors, Antigen, T-Cell/immunology | 7 | 3.0 |
Cell Division | 10 | 0.0 |
Encephalomyelitis, Autoimmune, Experimental/drug therapy/*immunology | 2 | 100.0 |
Epitopes, T-Lymphocyte/immunology | 3 | 3.0 |
HLA-DR2 Antigen/*immunology | 5 | 55.0 |
Immunodominant Epitopes/immunology | 4 | 20.0 |
T-Lymphocytes/cytology/*immunology | 4 | 3.0 |
Cells, Cultured | 80 | 0.0 |
HLA-DR Antigens/*immunology | 4 | 3.0 |
Multiple Sclerosis/blood/*immunology | 8 | 61.0 |
Myelin Basic Proteins/*immunology/pharmacology | 5 | 100.0 |
Peptide Mapping | 5 | 1.0 |
Time Factors | 36 | 0.0 |
Gene Expression/immunology | 2 | 2.0 |
Magnetic Resonance Imaging | 17 | 1.0 |
Oligoclonal Bands | 2 | 28.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
RNA, Messenger/analysis | 11 | 0.0 |
T-Lymphocytes/immunology | 29 | 2.0 |
Brain/pathology | 7 | 2.0 |
*Immunotherapy, Active | 2 | 8.0 |
T-Lymphocytes/immunology/*transplantation | 2 | 66.0 |
Treatment Outcome | 10 | 0.0 |
*Gene Expression | 5 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Binding Sites | 41 | 0.0 |
Carrier Proteins/metabolism | 8 | 1.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 7 | 0.0 |
Sequence Alignment | 17 | 0.0 |
In Vitro | 38 | 0.0 |
Kinetics | 45 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 10 | 1.0 |
Peptides/metabolism | 3 | 1.0 |
Phosphorylation | 38 | 0.0 |
Serine/metabolism | 2 | 0.0 |
Structure-Activity Relationship | 26 | 0.0 |
Substrate Specificity | 20 | 0.0 |
Age Factors | 13 | 0.0 |
Cell Differentiation/*genetics | 3 | 3.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Membrane Glycoproteins/metabolism | 3 | 0.0 |
Stem Cells/cytology/*metabolism | 3 | 8.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Up-Regulation/physiology | 2 | 1.0 |
Disease Progression | 7 | 0.0 |
Lymphocyte Count | 9 | 1.0 |
Myelin Basic Proteins/*immunology | 151 | 91.0 |
Pilot Projects | 3 | 0.0 |
Vaccination/*methods | 2 | 33.0 |
Autoantibodies/*blood/immunology | 2 | 8.0 |
Enzyme-Linked Immunosorbent Assay/methods | 9 | 3.0 |
Multiple Sclerosis/*blood/immunology | 3 | 75.0 |
Myelin Basic Proteins/analysis/*immunology | 4 | 100.0 |
Sensitivity and Specificity | 12 | 0.0 |
Biological Markers/analysis | 4 | 0.0 |
Brain Chemistry | 12 | 4.0 |
Nerve Tissue Proteins/analysis | 2 | 2.0 |
Antibodies, Monoclonal/*immunology | 12 | 1.0 |
Immunoglobulin E/*immunology | 2 | 8.0 |
Proteins | 2 | 3.0 |
Recombinant Proteins/immunology | 10 | 2.0 |
Administration, Inhalation | 2 | 1.0 |
Administration, Oral | 9 | 0.0 |
Anti-Inflammatory Agents/administration & dosage/*therapeutic use | 2 | 22.0 |
Inflammation/immunology | 2 | 1.0 |
Leukocyte Count | 15 | 0.0 |
Methylprednisolone/administration & dosage/*therapeutic use | 3 | 37.0 |
Culture Techniques | 2 | 0.0 |
Myelin-Associated Glycoprotein/metabolism | 3 | 33.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Neurons/physiology | 2 | 1.0 |
Rats, Sprague-Dawley | 11 | 0.0 |
Alleles | 29 | 0.0 |
Carrier Proteins/*genetics | 12 | 0.0 |
Collectins | 53 | 63.0 |
DNA/genetics | 10 | 0.0 |
Gene Frequency | 17 | 0.0 |
Genotype | 21 | 0.0 |
Glomerulonephritis, IGA/*genetics/immunology | 2 | 66.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Myelin Basic Proteins/genetics/metabolism | 5 | 100.0 |
RNA/metabolism | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
Cloning, Molecular | 53 | 0.0 |
Gene Library | 2 | 0.0 |
In Situ Hybridization | 14 | 0.0 |
Organ Specificity | 4 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
*ATP-Binding Cassette Transporters | 27 | 23.0 |
Amylose/chemistry | 2 | 66.0 |
Carrier Proteins/chemistry | 3 | 7.0 |
Chromatography | 2 | 1.0 |
Down-Regulation | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 52 | 1.0 |
Escherichia coli/metabolism | 5 | 1.0 |
*Escherichia coli Proteins | 27 | 12.0 |
Interferon Type II/metabolism | 6 | 2.0 |
*Monosaccharide Transport Proteins | 27 | 69.0 |
Open Reading Frames | 2 | 0.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 2 | 1.0 |
Autoantigens/immunology | 16 | 11.0 |
Multiple Sclerosis/*immunology/*therapy | 2 | 40.0 |
Brain/*metabolism | 11 | 2.0 |
Cercopithecus aethiops | 4 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics/*metabolism | 2 | 4.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Tissue Distribution | 10 | 0.0 |
Antibody Specificity/immunology | 3 | 4.0 |
Epitope Mapping/*methods | 2 | 14.0 |
Epitopes/*immunology | 14 | 6.0 |
Glial Fibrillary Acidic Protein/metabolism | 14 | 6.0 |
Guinea Pigs | 67 | 8.0 |
Immunohistochemistry/*methods | 3 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 71 | 0.0 |
Fetus | 7 | 1.0 |
Gene Expression Regulation, Developmental/physiology | 2 | 2.0 |
Myelin Basic Proteins/*genetics | 45 | 97.0 |
Myelin Sheath/metabolism/ultrastructure | 2 | 66.0 |
RNA, Messenger/metabolism | 15 | 0.0 |
Axons/metabolism | 2 | 5.0 |
Microscopy, Confocal | 3 | 0.0 |
Myelin Sheath/*physiology | 18 | 60.0 |
Oligodendroglia/cytology/*physiology | 2 | 25.0 |
Blotting, Northern | 15 | 0.0 |
Cell Survival | 3 | 0.0 |
Myelin Basic Proteins/genetics/*metabolism | 4 | 80.0 |
Oligodendroglia/drug effects/*metabolism | 2 | 100.0 |
Antibodies, Bacterial/*blood | 3 | 6.0 |
*Disease Models, Animal | 3 | 0.0 |
Immunoglobulin G/blood | 5 | 1.0 |
Polymerase Chain Reaction | 36 | 0.0 |
Recombinant Proteins/genetics/immunology/isolation & purification | 2 | 40.0 |
*Antigen Presentation | 6 | 3.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Immunodominant Epitopes/*immunology | 8 | 27.0 |
Mice, Inbred BALB C | 29 | 0.0 |
Myelin Basic Proteins/*immunology/metabolism | 11 | 100.0 |
Encephalomyelitis, Autoimmune, Experimental/etiology | 3 | 100.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Microscopy, Electron | 19 | 0.0 |
Encephalomyelitis, Autoimmune, Experimental/*drug therapy/pathology | 2 | 100.0 |
Epitopes | 26 | 2.0 |
Ligands | 8 | 0.0 |
Magnetic Resonance Spectroscopy | 9 | 1.0 |
Models, Molecular | 19 | 0.0 |
Rats, Inbred Lew | 38 | 14.0 |
Spinal Cord/pathology | 7 | 9.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Calcium/metabolism | 7 | 0.0 |
Myelin Basic Proteins/*metabolism/pharmacology | 2 | 100.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Peptide Fragments/pharmacology | 4 | 1.0 |
Tumor Cells, Cultured | 26 | 0.0 |
Peptide Fragments/immunology/metabolism | 4 | 8.0 |
Myelin Basic Proteins/*metabolism | 38 | 84.0 |
Antibodies | 7 | 1.0 |
Base Sequence | 127 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Immunotherapy/*methods | 3 | 2.0 |
Neutralization Tests | 4 | 0.0 |
Plasmids/genetics | 3 | 0.0 |
Rabbits | 47 | 1.0 |
Recombinant Fusion Proteins/genetics/immunology | 4 | 8.0 |
Biopsy | 3 | 0.0 |
Blood Proteins/metabolism | 6 | 2.0 |
Chronic Disease | 12 | 0.0 |
Eosinophil Granule Proteins | 66 | 30.0 |
Image Processing, Computer-Assisted | 5 | 1.0 |
Neutrophils/pathology | 2 | 3.0 |
*Ribonucleases | 63 | 30.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
*Gene Expression Regulation | 11 | 0.0 |
Hela Cells | 21 | 0.0 |
Myelin Basic Proteins/genetics | 9 | 75.0 |
Point Mutation | 8 | 0.0 |
Promoter Regions (Genetics) | 12 | 0.0 |
Protein Binding | 33 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Transcription Factors/*physiology | 2 | 0.0 |
X Chromosome | 2 | 0.0 |
Adjuvants, Immunologic/therapeutic use | 2 | 4.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Longitudinal Studies | 8 | 0.0 |
Myelin Basic Proteins/pharmacology | 12 | 92.0 |
Autoantibodies/*blood | 9 | 3.0 |
Immunoglobulin A/blood | 2 | 1.0 |
Immunoglobulin M/blood | 3 | 2.0 |
Multiple Sclerosis/*immunology | 69 | 63.0 |
Myelin-Associated Glycoprotein/*immunology | 8 | 25.0 |
Antibodies, Bacterial/blood | 2 | 2.0 |
Brain Chemistry/immunology | 2 | 40.0 |
Indicator Dilution Techniques | 2 | 10.0 |
Cytokines/metabolism | 3 | 0.0 |
Antigen-Presenting Cells/physiology | 2 | 3.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Lymphocyte Activation | 49 | 1.0 |
*Phagocytosis | 3 | 2.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 5 | 0.0 |
Infant | 33 | 0.0 |
Myelin Basic Proteins/*cerebrospinal fluid | 36 | 100.0 |
S100 Proteins/*cerebrospinal fluid | 5 | 62.0 |
Chromatography, Gel | 16 | 1.0 |
Protein Structure, Secondary | 11 | 1.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Temperature | 7 | 0.0 |
Dimerization | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 62 | 1.0 |
Protein Folding | 5 | 1.0 |
*Repressor Proteins | 2 | 0.0 |
Scattering, Radiation | 3 | 2.0 |
Solubility/drug effects | 2 | 22.0 |
Clone Cells | 23 | 2.0 |
Lymphocyte Activation/*immunology | 6 | 1.0 |
Myelin Proteins/*immunology | 22 | 25.0 |
Myelin Proteolipid Protein/immunology | 4 | 50.0 |
Optic Nerve/*pathology | 2 | 100.0 |
Peptide Fragments/*immunology | 19 | 18.0 |
Cell Line | 79 | 0.0 |
DNA, Recombinant/genetics | 2 | 3.0 |
*Genetic Vectors | 3 | 0.0 |
Transfection | 20 | 0.0 |
Cross Reactions | 31 | 3.0 |
Cytokines/biosynthesis | 5 | 0.0 |
Immunosuppressive Agents/*therapeutic use | 3 | 2.0 |
Multiple Sclerosis/*drug therapy/*immunology | 6 | 66.0 |
Peptides/*pharmacology | 7 | 3.0 |
Regression Analysis | 5 | 0.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Enzyme Activation | 25 | 0.0 |
*Linkage (Genetics) | 5 | 0.0 |
Multiple Sclerosis/*genetics/immunology | 4 | 23.0 |
Phenotype | 22 | 0.0 |
Calpain/*metabolism | 2 | 13.0 |
Demyelinating Diseases/*metabolism | 2 | 10.0 |
Encephalomyelitis, Autoimmune, Experimental/metabolism | 2 | 66.0 |
Myelin Sheath/*metabolism | 6 | 16.0 |
Electrochemistry | 6 | 6.0 |
Isomerism | 10 | 4.0 |
Molecular Weight | 42 | 1.0 |
Myelin Basic Proteins/chemistry/genetics/*metabolism | 2 | 100.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Antibodies/pharmacology | 2 | 0.0 |
Dose-Response Relationship, Drug | 19 | 0.0 |
HLA-DR2 Antigen/*metabolism | 4 | 80.0 |
Immunodominant Epitopes/*metabolism | 2 | 100.0 |
Multiple Sclerosis/immunology | 17 | 41.0 |
Myelin Basic Proteins/chemistry/immunology/*metabolism | 4 | 100.0 |
Protein Binding/drug effects | 3 | 0.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
HLA-DR Antigens/genetics | 6 | 1.0 |
Histocompatibility Testing | 4 | 0.0 |
Tuberculin/immunology | 3 | 5.0 |
*Alleles | 7 | 0.0 |
English Abstract | 50 | 0.0 |
*Polymorphism, Genetic | 9 | 0.0 |
Cell Movement/physiology | 3 | 1.0 |
S100 Proteins/metabolism | 3 | 2.0 |
Fluorescent Antibody Technique | 15 | 0.0 |
Antigens, CD57/analysis | 3 | 6.0 |
Immunoenzyme Techniques | 27 | 0.0 |
Phosphopyruvate Hydratase/analysis | 7 | 9.0 |
S100 Proteins/analysis | 12 | 6.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Aging/physiology | 2 | 1.0 |
Animals, Newborn | 5 | 0.0 |
Antigens, Differentiation/metabolism | 3 | 2.0 |
Astrocytes/cytology/*metabolism | 2 | 11.0 |
Callithrix | 2 | 2.0 |
Cats | 2 | 0.0 |
Sheep | 11 | 1.0 |
Multiple Sclerosis/*pathology | 4 | 28.0 |
Molecular Mimicry/*immunology | 2 | 28.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
*Conserved Sequence | 4 | 2.0 |
Plasmids | 7 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Prevalence | 2 | 0.0 |
DNA Methylation | 2 | 0.0 |
DNA-Binding Proteins/*chemistry/metabolism | 2 | 2.0 |
Oxidative Stress | 2 | 0.0 |
Antigen-Antibody Complex/*metabolism | 2 | 2.0 |
Carrier Proteins/blood/*genetics | 8 | 24.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Cytoplasmic Granules/chemistry | 2 | 10.0 |
Cytotoxicity, Immunologic | 13 | 1.0 |
Eosinophils/metabolism | 6 | 21.0 |
Evolution, Molecular | 3 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Pregnancy | 23 | 0.0 |
Sequence Homology | 3 | 0.0 |
Transcription, Genetic | 17 | 0.0 |
Binding, Competitive | 16 | 0.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 8 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Antigens, Bacterial/*immunology | 2 | 1.0 |
Genetic Complementation Test | 2 | 0.0 |
*Periplasmic Binding Proteins | 3 | 42.0 |
Antibodies, Monoclonal/immunology | 14 | 0.0 |
Antibody Specificity | 26 | 1.0 |
Epitope Mapping | 5 | 1.0 |
Protein Transport | 2 | 0.0 |
Blood Pressure | 3 | 0.0 |
Posture | 2 | 2.0 |
Biological Markers/blood | 2 | 0.0 |
Interferon Type II/*biosynthesis | 4 | 2.0 |
Mice, Transgenic | 28 | 0.0 |
T-Lymphocytes/drug effects/immunology | 2 | 2.0 |
Vaccination | 6 | 3.0 |
*Autoimmunity | 8 | 12.0 |
Cytokines/*biosynthesis | 3 | 0.0 |
Epitopes/immunology | 23 | 4.0 |
Myelin Basic Proteins/chemistry/*immunology | 13 | 92.0 |
Peptides/immunology | 10 | 7.0 |
Stem Cells/immunology | 2 | 6.0 |
T-Lymphocytes/*immunology/metabolism | 4 | 2.0 |
Protein Conformation | 27 | 0.0 |
Cell Membrane Permeability | 2 | 1.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Mutagenesis | 4 | 0.0 |
Binding Sites/genetics | 7 | 0.0 |
Gene Expression Regulation, Developmental/*genetics | 2 | 2.0 |
Myelin Basic Proteins/*genetics/metabolism | 6 | 100.0 |
Oligodendroglia/cytology/*metabolism | 5 | 33.0 |
Horses | 3 | 2.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Species Specificity | 21 | 0.0 |
Autoantigens/*immunology | 23 | 14.0 |
Myelin Sheath/immunology | 7 | 41.0 |
Peptide Fragments/immunology/pharmacology | 2 | 16.0 |
Receptors, Antigen, T-Cell/*immunology | 5 | 2.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Microsatellite Repeats | 2 | 0.0 |
Multiple Sclerosis/*genetics | 9 | 11.0 |
DNA Primers/genetics | 6 | 0.0 |
Risk Factors | 7 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 3 | 1.0 |
Amino Acid Motifs | 2 | 0.0 |
Disease Models, Animal | 35 | 1.0 |
Encephalomyelitis, Autoimmune, Experimental/*immunology | 27 | 79.0 |
CHO Cells | 9 | 0.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Hamsters | 11 | 0.0 |
Lipopolysaccharides/*metabolism | 2 | 1.0 |
*Mannose-Binding Lectin | 2 | 100.0 |
Water/chemistry | 2 | 5.0 |
DNA, Bacterial/genetics | 3 | 4.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Gene Expression | 23 | 0.0 |
Interferon Type II/blood | 4 | 3.0 |
Crystallography, X-Ray | 10 | 1.0 |
Myelin Basic Proteins/chemistry | 2 | 66.0 |
Cell Separation | 6 | 0.0 |
Injections, Subcutaneous | 4 | 1.0 |
Lymphocyte Activation/immunology | 8 | 1.0 |
Myelin Basic Proteins/administration & dosage/immunology | 5 | 83.0 |
Peptide Fragments/*immunology/*metabolism | 2 | 40.0 |
Immunosuppressive Agents/*pharmacology | 6 | 2.0 |
Jurkat Cells | 4 | 0.0 |
Lymphocyte Activation/*drug effects/immunology | 2 | 9.0 |
*Potassium Channels, Voltage-Gated | 2 | 0.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/biosynthesis | 2 | 9.0 |
Mutation | 11 | 0.0 |
Myelin Basic Proteins/*genetics/physiology | 2 | 100.0 |
Oligodendroglia/*physiology | 5 | 45.0 |
*Membrane Glycoproteins | 3 | 0.0 |
Models, Immunological | 2 | 0.0 |
Autoantibodies/blood | 2 | 1.0 |
Immunoglobulin M/*blood | 2 | 5.0 |
Peptide Fragments/immunology | 25 | 10.0 |
Waldenstrom Macroglobulinemia/*immunology | 2 | 40.0 |
Malaria, Cerebral/*genetics/*immunology | 3 | 75.0 |
3T3 Cells | 2 | 0.0 |
Antigen-Presenting Cells/immunology | 8 | 2.0 |
Cell Line, Transformed | 9 | 0.0 |
Neurons/immunology | 2 | 33.0 |
Flow Cytometry | 15 | 0.0 |
Progesterone/pharmacology/*physiology | 2 | 33.0 |
Schwann Cells/drug effects/physiology | 2 | 100.0 |
Remission, Spontaneous | 3 | 4.0 |
Haplorhini | 8 | 2.0 |
*Lymphocyte Activation | 10 | 0.0 |
Polymorphism, Genetic | 11 | 0.0 |
Cluster Analysis | 2 | 1.0 |
Myelin Basic Proteins/biosynthesis/genetics | 5 | 100.0 |
Up-Regulation/genetics/immunology | 2 | 3.0 |
Multiple Sclerosis/genetics/immunology | 4 | 50.0 |
Peptide Fragments/chemistry/immunology | 2 | 3.0 |
Autoantibodies/*cerebrospinal fluid | 6 | 100.0 |
Immunosuppression | 4 | 2.0 |
Injections, Intravenous | 8 | 1.0 |
Myelin Proteolipid Protein/*immunology | 3 | 60.0 |
Encephalomyelitis, Autoimmune, Experimental/*drug therapy | 4 | 100.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Recurrence | 23 | 1.0 |
Spinal Cord/metabolism/pathology | 3 | 14.0 |
Cloning, Molecular/methods | 3 | 1.0 |
Escherichia coli/genetics | 12 | 2.0 |
Hydrogen-Ion Concentration | 17 | 1.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Multiple Sclerosis/cerebrospinal fluid | 3 | 42.0 |
Radioimmunoassay | 40 | 2.0 |
DNA Primers | 9 | 0.0 |
DNA, Complementary | 9 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Myelin Basic Proteins/chemistry/*immunology/pharmacology | 2 | 100.0 |
T-Lymphocytes/drug effects/*immunology | 3 | 2.0 |
Myelin Basic Proteins | 2 | 100.0 |
Random Allocation | 2 | 0.0 |
Inflammation | 3 | 0.0 |
Mice, Inbred C57BL | 15 | 0.0 |
*Mice, Transgenic | 2 | 4.0 |
Multiple Sclerosis/metabolism | 6 | 66.0 |
Myelin Basic Proteins/*chemistry/metabolism | 5 | 83.0 |
Interferon Type II/*metabolism | 2 | 3.0 |
Microscopy, Electron, Scanning | 4 | 1.0 |
Peptide Fragments/metabolism | 5 | 1.0 |
Adjuvants, Immunologic/*therapeutic use | 2 | 2.0 |
Immunoblotting | 24 | 1.0 |
Interferon-beta/*therapeutic use | 3 | 13.0 |
Interleukin-10/metabolism | 2 | 3.0 |
Interleukin-4/metabolism | 3 | 3.0 |
T-Lymphocytes/immunology/metabolism | 2 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Embryo | 2 | 0.0 |
S100 Proteins/*metabolism | 2 | 3.0 |
Arginine/genetics | 2 | 1.0 |
Aspartic Acid/genetics | 3 | 4.0 |
Complement Fixation Tests | 3 | 3.0 |
Cysteine/genetics | 2 | 1.0 |
Glutamic Acid/genetics | 2 | 5.0 |
Glycine/genetics | 3 | 3.0 |
Lysine/metabolism | 2 | 2.0 |
Mannans/metabolism | 4 | 26.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Protein Processing, Post-Translational | 11 | 1.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Freund's Adjuvant | 5 | 45.0 |
Immunization, Passive | 2 | 2.0 |
Lymphocyte Activation/drug effects | 7 | 1.0 |
Multiple Sclerosis/*drug therapy | 3 | 30.0 |
Astrocytoma/pathology | 2 | 16.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Genetics, Population | 2 | 0.0 |
Japan | 3 | 0.0 |
Paternity | 2 | 2.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Tandem Repeat Sequences/*genetics | 2 | 2.0 |
B-Lymphocytes/*immunology | 9 | 1.0 |
Crosses, Genetic | 5 | 0.0 |
Muramidase/immunology | 2 | 14.0 |
Myelin Basic Proteins/*genetics/immunology | 5 | 100.0 |
Antigen Presentation/immunology | 2 | 2.0 |
Autoantigens/genetics/immunology | 2 | 28.0 |
Encephalomyelitis, Autoimmune, Experimental/immunology | 7 | 50.0 |
Follow-Up Studies | 10 | 0.0 |
HLA-DR2 Antigen/immunology | 2 | 66.0 |
Myelin Basic Proteins/*genetics/*immunology | 3 | 100.0 |
Cytokines/immunology | 2 | 1.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Blood Proteins/*metabolism | 11 | 5.0 |
Cytokines/*metabolism | 2 | 0.0 |
Fetal Blood/*immunology | 3 | 3.0 |
Growth | 2 | 4.0 |
Staining and Labeling | 7 | 1.0 |
Chromosome Mapping | 13 | 0.0 |
Protease Inhibitors/pharmacology | 5 | 2.0 |
Vero Cells | 2 | 0.0 |
Heparin/*metabolism | 2 | 2.0 |
Hydrolysis | 9 | 1.0 |
Repetitive Sequences, Amino Acid | 2 | 1.0 |
Sequence Deletion | 10 | 0.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Polymers/metabolism | 3 | 6.0 |
Sequence Analysis, Protein | 2 | 1.0 |
Spectrum Analysis, Mass | 8 | 1.0 |
Brain/*pathology | 6 | 3.0 |
Cell Count | 4 | 0.0 |
Neurons/pathology | 2 | 1.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Multiple Sclerosis/genetics/*immunology | 9 | 45.0 |
Myelin Basic Proteins/genetics/*immunology | 6 | 100.0 |
Peptide Fragments/genetics/immunology | 3 | 8.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Glycogen Synthase Kinase 3 | 7 | 7.0 |
JNK Mitogen-Activated Protein Kinases | 5 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 5 | 0.0 |
Drug Synergism | 5 | 0.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Immunophenotyping | 7 | 0.0 |
Myelin Sheath/*immunology | 4 | 30.0 |
Quadriplegia/etiology | 2 | 66.0 |
Superantigens/immunology | 2 | 4.0 |
Autoimmunity | 6 | 4.0 |
*Vaccination | 4 | 7.0 |
Biological Transport/physiology | 2 | 1.0 |
Oligodendroglia/*metabolism | 6 | 26.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Solubility | 14 | 1.0 |
Swine | 9 | 0.0 |
Tunica Intima/pathology | 2 | 7.0 |
Chromatography, Liquid | 4 | 3.0 |
Cell Differentiation/*drug effects | 2 | 1.0 |
Macrophage-1 Antigen/metabolism | 2 | 2.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Genetic Predisposition to Disease | 11 | 0.0 |
HLA-DR2 Antigen/genetics | 2 | 11.0 |
Homozygote | 5 | 0.0 |
Mutation/*genetics | 3 | 0.0 |
Epitopes, T-Lymphocyte/*immunology | 3 | 5.0 |
Immunologic Memory | 2 | 0.0 |
Immunotherapy | 6 | 1.0 |
Mice, Inbred Strains | 29 | 3.0 |
Organ Culture Techniques | 2 | 0.0 |
Ovalbumin/immunology | 3 | 6.0 |
Arginine/chemistry | 3 | 4.0 |
Citrulline/*analysis | 2 | 66.0 |
Macromolecular Substances | 10 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Chromosomes, Human, Pair 6/*genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Restriction Mapping | 14 | 0.0 |
Antibody Affinity/*immunology | 2 | 25.0 |
Cytoskeleton/*metabolism | 2 | 1.0 |
Myelin Sheath/metabolism | 6 | 28.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Protein Kinases/metabolism | 4 | 0.0 |
*Signal Transduction | 3 | 0.0 |
Thymidine/metabolism | 2 | 0.0 |
Myelin Basic Proteins/*physiology | 3 | 100.0 |
Neurons/*physiology | 2 | 1.0 |
Brain/*immunology | 5 | 20.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Nerve Tissue Proteins/*immunology | 6 | 27.0 |
Protein Kinase C/metabolism | 3 | 0.0 |
Adoptive Transfer | 2 | 2.0 |
Gene Therapy/*methods | 2 | 0.0 |
Genetic Vectors | 8 | 0.0 |
Immunoglobulin G/immunology | 5 | 1.0 |
Myelin Basic Proteins/immunology/*metabolism | 7 | 100.0 |
Peptide Fragments/immunology/*metabolism | 2 | 15.0 |
Protein Binding/immunology | 10 | 5.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Circular Dichroism | 5 | 1.0 |
Exons | 15 | 0.0 |
Liposomes | 3 | 1.0 |
Membrane Lipids/*metabolism | 2 | 6.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Genes, Immunoglobulin | 3 | 1.0 |
Histocompatibility Antigens Class II/*genetics/immunology | 2 | 10.0 |
Immunoglobulin Variable Region/genetics/immunology | 2 | 10.0 |
Multiple Sclerosis/*genetics/*immunology | 4 | 36.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 6 | 8.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
HLA-DR2 Antigen/genetics/*immunology | 2 | 66.0 |
Multiple Sclerosis/*genetics/*immunology/pathology | 2 | 100.0 |
Pertussis Toxin | 2 | 1.0 |
Receptors, Antigen, T-Cell/genetics/*immunology | 3 | 18.0 |
Carrier Proteins/genetics | 12 | 3.0 |
Cell Division/immunology | 5 | 1.0 |
Escherichia coli/*metabolism | 2 | 7.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Family Health | 2 | 0.0 |
Genetic Markers | 5 | 0.0 |
Myelin Proteolipid Protein/*genetics | 4 | 44.0 |
COS Cells | 5 | 0.0 |
Mannose-Binding Lectins | 39 | 78.0 |
Recombinant Fusion Proteins/immunology | 4 | 3.0 |
*Magnetic Resonance Imaging | 6 | 3.0 |
Thalamus/*pathology | 2 | 40.0 |
Immunity, Natural | 4 | 1.0 |
Injections, Intradermal | 2 | 4.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/metabolism | 2 | 1.0 |
Mutation/genetics | 3 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Gene Expression Regulation | 10 | 0.0 |
Introns | 2 | 0.0 |
*Promoter Regions (Genetics) | 11 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Blood Platelets/physiology | 2 | 3.0 |
Endothelium, Vascular/physiology | 3 | 4.0 |
*Immunogenetics | 2 | 16.0 |
Leukocytes/physiology | 2 | 3.0 |
Macrophages/physiology | 4 | 5.0 |
Pulmonary Surfactant-Associated Protein A | 8 | 25.0 |
Pulmonary Surfactant-Associated Protein D | 8 | 50.0 |
Pulmonary Surfactant-Associated Proteins | 8 | 22.0 |
Cell Division/drug effects | 7 | 0.0 |
Recombinant Proteins/pharmacology | 12 | 0.0 |
Myelin Proteins/*genetics | 7 | 6.0 |
Myelin-Associated Glycoprotein/analysis | 2 | 40.0 |
Multiple Sclerosis/blood/cerebrospinal fluid/*immunology | 8 | 53.0 |
Retrospective Studies | 6 | 0.0 |
Blood Proteins/*analysis | 6 | 4.0 |
Eosinophil-Derived Neurotoxin | 9 | 11.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Antigens, Bacterial/genetics | 2 | 22.0 |
Serologic Tests/*methods/statistics & numerical data | 2 | 100.0 |
Autoantigens | 3 | 9.0 |
Biological Markers | 13 | 0.0 |
Silver Staining | 3 | 3.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Interferon Type II/secretion | 3 | 2.0 |
Interleukin-4/secretion | 2 | 4.0 |
T-Lymphocyte Subsets/*immunology | 5 | 0.0 |
Autoantibodies/*immunology | 6 | 2.0 |
Heterozygote | 3 | 0.0 |
Mice, Neurologic Mutants | 3 | 2.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Gliosis/pathology | 2 | 11.0 |
Hypoxia, Brain/*pathology | 2 | 40.0 |
Infant, Newborn | 29 | 0.0 |
C-Reactive Protein/*analysis | 2 | 0.0 |
Carrier Proteins/*blood | 9 | 3.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 10 | 3.0 |
Calcium/*metabolism | 2 | 0.0 |
Enzyme Activation/drug effects | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Ionophores/pharmacology | 2 | 1.0 |
Mitogen-Activated Protein Kinase 1 | 7 | 5.0 |
Mitogen-Activated Protein Kinase Kinases | 2 | 5.0 |
*Mitogen-Activated Protein Kinases | 13 | 3.0 |
*Immune Tolerance | 7 | 4.0 |
Receptors, Antigen, T-Cell/*genetics | 7 | 7.0 |
Citrulline/chemistry | 3 | 100.0 |
Multiple Sclerosis/*physiopathology | 2 | 15.0 |
Epitopes/chemistry/immunology | 2 | 4.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
Th1 Cells/immunology | 4 | 2.0 |
Interleukin-8/*biosynthesis | 2 | 3.0 |
Proteins/metabolism | 2 | 0.0 |
Oligodendroglia/metabolism | 5 | 12.0 |
RNA, Messenger/*genetics | 4 | 1.0 |
Blood Proteins/analysis | 5 | 3.0 |
Glycoproteins/*chemistry | 2 | 9.0 |
Lectins | 4 | 4.0 |
*Protein Conformation | 4 | 1.0 |
Pulmonary Surfactants/*chemistry | 2 | 66.0 |
Recombinant Fusion Proteins/chemistry | 2 | 2.0 |
Stimulation, Chemical | 4 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 4 | 1.0 |
Glutathione Transferase | 2 | 4.0 |
Precipitation | 2 | 1.0 |
Antigen-Presenting Cells/*physiology | 2 | 5.0 |
Antigens/*immunology | 4 | 5.0 |
Flow Cytometry/methods | 2 | 0.0 |
Sputum/*cytology | 2 | 18.0 |
Antibodies, Viral/blood | 2 | 1.0 |
Antigens, Viral/immunology | 4 | 3.0 |
Brain/metabolism | 6 | 0.0 |
Cathepsin D/metabolism | 2 | 5.0 |
Citrulline/*metabolism | 2 | 40.0 |
Chromatography, Affinity | 12 | 1.0 |
Escherichia coli/*genetics | 3 | 3.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 3 | 2.0 |
Phytohemagglutinins/immunology | 2 | 4.0 |
Carrier Proteins/*metabolism | 12 | 1.0 |
Peptide Library | 2 | 1.0 |
Recombinant Fusion Proteins | 3 | 0.0 |
Anion Exchange Resins | 3 | 42.0 |
Chromatography, High Pressure Liquid | 13 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 6 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Oligodendroglioma/genetics/metabolism | 2 | 100.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
Immunity, Natural/genetics | 2 | 3.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 6 | 8.0 |
Antibody Formation | 12 | 2.0 |
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 2 | 12.0 |
Escherichia coli | 10 | 2.0 |
Phosphorylation/drug effects | 4 | 0.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Iodine Radioisotopes | 4 | 1.0 |
Tritium | 2 | 0.0 |
Syndrome | 7 | 0.0 |
Adenosinetriphosphatase/*chemistry/metabolism | 2 | 22.0 |
Recombinant Proteins | 3 | 0.0 |
Carrier Proteins/*chemistry | 2 | 3.0 |
Placenta/chemistry | 2 | 6.0 |
Autopsy | 2 | 1.0 |
Hyperplasia | 2 | 0.0 |
Citrulline/analysis | 3 | 100.0 |
*Mutation | 3 | 0.0 |
Heat | 6 | 1.0 |
Peptide Fragments/chemistry | 3 | 1.0 |
Protein Denaturation | 2 | 0.0 |
Spectrometry, Mass, Electrospray Ionization | 2 | 2.0 |
Finland/epidemiology | 4 | 3.0 |
*Antibody Formation | 3 | 3.0 |
*Immunity, Cellular | 8 | 6.0 |
Glycosylation | 8 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/isolation & purification | 3 | 21.0 |
Baculoviridae | 2 | 3.0 |
Carrier Proteins | 2 | 3.0 |
Recombinant Proteins/biosynthesis/isolation & purification | 2 | 7.0 |
Cerebrospinal Fluid/cytology | 4 | 16.0 |
Immunoglobulin G/cerebrospinal fluid | 7 | 43.0 |
Myelin Basic Proteins/cerebrospinal fluid | 5 | 83.0 |
Maltose/metabolism | 5 | 71.0 |
Administration, Intranasal | 2 | 2.0 |
Interferon Type II/analysis | 2 | 2.0 |
Interleukin-5/analysis | 2 | 15.0 |
Clone Cells/immunology | 6 | 3.0 |
Peptides/*immunology | 5 | 7.0 |
Binding Sites/physiology | 2 | 1.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Myelin Sheath/chemistry | 2 | 50.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
Mannose/pharmacology | 3 | 25.0 |
Antigen Presentation | 5 | 1.0 |
Hybridomas | 4 | 2.0 |
Myelin Basic Proteins/immunology/metabolism | 3 | 50.0 |
Apoptosis | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Blotting, Southern | 11 | 0.0 |
Carrier Proteins/*blood/genetics | 4 | 21.0 |
Chi-Square Distribution | 5 | 0.0 |
Prospective Studies | 7 | 0.0 |
Evaluation Studies | 3 | 0.0 |
Immune Sera | 4 | 1.0 |
Reference Standards | 4 | 1.0 |
Reproducibility of Results | 4 | 0.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Cadaver | 2 | 0.0 |
*Diseases in Twins | 2 | 6.0 |
Embryonic and Fetal Development/physiology | 3 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 3 | 1.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Interleukin-3/*pharmacology | 3 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Edetic Acid/pharmacology | 6 | 3.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Survival Analysis | 4 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
Recombinant Fusion Proteins/genetics | 3 | 1.0 |
Myelin Basic Proteins/*chemistry | 4 | 100.0 |
Autoimmunity/immunology | 2 | 6.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Lymph Nodes/immunology | 5 | 5.0 |
Myelin Basic Proteins/*administration & dosage | 4 | 100.0 |
Aging/*metabolism | 4 | 1.0 |
Cell Differentiation | 7 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Models, Genetic | 2 | 0.0 |
Myelin Basic Proteins/biosynthesis/*genetics | 4 | 100.0 |
*Complement Activation | 8 | 2.0 |
Multiple Sclerosis/cerebrospinal fluid/*immunology | 8 | 47.0 |
Myelin Basic Proteins/*cerebrospinal fluid/immunology | 4 | 100.0 |
RNA, Messenger/genetics | 8 | 0.0 |
Brain/*physiology | 2 | 1.0 |
Diastole | 2 | 2.0 |
Dogs | 6 | 0.0 |
Systole | 2 | 2.0 |
Cysteine Endopeptidases/genetics/*metabolism | 2 | 16.0 |
Peptides/chemical synthesis/metabolism | 3 | 27.0 |
*Viral Proteins | 4 | 2.0 |
Baculoviridae/genetics | 2 | 1.0 |
Crystallization | 3 | 1.0 |
Spodoptera | 3 | 1.0 |
*Genes, Viral | 3 | 1.0 |
Sequence Analysis | 5 | 1.0 |
Immunoassay | 3 | 1.0 |
Myelin Basic Proteins/*pharmacology | 10 | 100.0 |
Adjuvants, Immunologic/*pharmacology | 2 | 1.0 |
Multiple Sclerosis/*drug therapy/immunology | 3 | 21.0 |
Hemagglutination Inhibition Tests | 3 | 6.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
Transforming Growth Factor beta/biosynthesis/blood | 2 | 50.0 |
T-Lymphocytes/immunology/*physiology | 2 | 3.0 |
Amylose | 2 | 100.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Cross-Linking Reagents | 2 | 0.0 |
Oxidation-Reduction | 4 | 0.0 |
Methylprednisolone/*administration & dosage | 2 | 10.0 |
Tetanus Toxoid/immunology | 3 | 3.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 2 | 2.0 |
Signal Transduction | 5 | 0.0 |
Drug Therapy, Combination | 4 | 0.0 |
Multiple Sclerosis/*drug therapy/metabolism | 2 | 50.0 |
RNA, Messenger/isolation & purification | 2 | 2.0 |
Up-Regulation | 2 | 0.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Phosphoprotein Phosphatase/*metabolism | 3 | 3.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
Peptides/chemistry/immunology | 4 | 10.0 |
Clonal Anergy | 3 | 8.0 |
Encephalomyelitis, Autoimmune, Experimental/*prevention & control | 4 | 57.0 |
Immunoglobulin G/*immunology | 2 | 2.0 |
Encephalomyelitis, Autoimmune, Experimental/*physiopathology | 2 | 66.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Aging | 3 | 0.0 |
Mannose/*metabolism | 7 | 43.0 |
HLA-DR Antigens/analysis | 4 | 0.0 |
Carrier Proteins/*immunology | 3 | 6.0 |
Blood Proteins/*genetics | 4 | 2.0 |
Eosinophils/*physiology | 7 | 16.0 |
Complement Activation/physiology | 2 | 10.0 |
Phylogeny | 2 | 0.0 |
*Antigens, Bacterial | 2 | 3.0 |
Fimbriae, Bacterial/*physiology | 2 | 22.0 |
Transgenes | 2 | 0.0 |
*Chromosome Deletion | 4 | 0.0 |
Chromosomes, Human, Pair 18/*genetics | 3 | 3.0 |
Combined Modality Therapy | 2 | 0.0 |
Demyelinating Diseases/*chemically induced | 2 | 66.0 |
Drug Interactions | 3 | 0.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Centromere | 2 | 2.0 |
Chromosome Mapping/methods | 2 | 1.0 |
*Chromosomes, Human, Pair 10 | 2 | 1.0 |
Glycoproteins/*genetics | 2 | 1.0 |
Pulmonary Surfactants/*genetics | 2 | 15.0 |
Disease Susceptibility | 8 | 1.0 |
Genes, Structural | 7 | 0.0 |
Haplotypes/genetics | 3 | 0.0 |
*Microsatellite Repeats | 3 | 1.0 |
Multiple Sclerosis/epidemiology/*genetics | 3 | 23.0 |
Interleukin-2/pharmacology | 4 | 0.0 |
Gambia | 2 | 5.0 |
Macrophages/metabolism | 3 | 0.0 |
Vimentin/metabolism | 3 | 2.0 |
Antibodies, Monoclonal | 11 | 0.0 |
B-Lymphocytes/immunology | 4 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Antigens, Viral/*immunology | 4 | 4.0 |
Viral Envelope Proteins/*immunology | 3 | 7.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Antigens | 2 | 2.0 |
Axons/physiology | 2 | 4.0 |
Schwann Cells/metabolism | 3 | 12.0 |
Exons/genetics | 2 | 0.0 |
Autoantigens/genetics | 2 | 5.0 |
Blood Proteins/*pharmacology | 8 | 20.0 |
Histamine Release | 2 | 3.0 |
Myelin Basic Proteins/*analysis | 13 | 86.0 |
Peptide Fragments/*analysis | 2 | 4.0 |
Antigen Presentation/*immunology | 3 | 3.0 |
Autoimmune Diseases/immunology/*therapy | 3 | 25.0 |
Encephalomyelitis, Autoimmune, Experimental/immunology/therapy | 3 | 60.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Antigens/immunology | 4 | 2.0 |
Autoimmunity/*immunology | 7 | 15.0 |
Central Nervous System/*immunology | 5 | 38.0 |
Immune Tolerance | 8 | 2.0 |
Immunity, Cellular | 14 | 2.0 |
*Immunoenzyme Techniques | 2 | 1.0 |
Macaca fascicularis | 5 | 1.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Cytochalasin B/pharmacology | 3 | 3.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 4 | 1.0 |
Platelet Activating Factor/pharmacology | 2 | 4.0 |
Polylysine/pharmacology | 2 | 10.0 |
Antibodies, Viral/*blood | 3 | 6.0 |
Carrier Proteins/genetics/immunology | 2 | 20.0 |
Cytomegalovirus/*immunology | 2 | 3.0 |
Serotyping | 2 | 0.0 |
Complement Activation | 6 | 2.0 |
Mannans/*metabolism | 7 | 87.0 |
Proline/metabolism | 2 | 3.0 |
Recombination, Genetic | 2 | 0.0 |
Vaccinia virus/*genetics | 2 | 10.0 |
Interleukin-2/*biosynthesis | 3 | 2.0 |
Autoantibodies/immunology | 4 | 3.0 |
Haplotypes | 9 | 0.0 |
Multiple Sclerosis/immunology/*therapy | 2 | 22.0 |
Oligodendroglia/immunology | 2 | 40.0 |
T-Lymphocyte Subsets/immunology | 3 | 0.0 |
Antibodies/immunology | 4 | 1.0 |
Histocytochemistry | 12 | 1.0 |
Gestational Age | 13 | 1.0 |
Escherichia coli/*genetics/metabolism | 3 | 20.0 |
Brain/embryology/*growth & development | 2 | 40.0 |
Embryonic and Fetal Development | 3 | 0.0 |
Myelin Sheath/physiology | 10 | 55.0 |
Spinal Cord/metabolism | 3 | 5.0 |
Protein Binding/physiology | 3 | 1.0 |
Multiple Sclerosis/blood/etiology/*immunology | 2 | 100.0 |
Phytohemagglutinins/pharmacology | 3 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
DNA/analysis/genetics | 2 | 1.0 |
*Genes, Structural | 8 | 0.0 |
Myelin Proteolipid Protein/genetics | 3 | 30.0 |
Neuroglia/*physiology | 5 | 17.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/*immunology | 4 | 22.0 |
Osmolar Concentration | 2 | 0.0 |
Peptide Hydrolases/*cerebrospinal fluid | 2 | 100.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Methods | 3 | 1.0 |
*HIV-1 | 2 | 0.0 |
Myelin Basic Proteins/biosynthesis | 2 | 100.0 |
Myelin Sheath/drug effects/*metabolism | 2 | 66.0 |
Nucleic Acid Conformation | 2 | 0.0 |
*Bacterial Adhesion | 2 | 4.0 |
Opsonins/chemistry | 2 | 100.0 |
Th2 Cells/immunology | 2 | 1.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Cytokines/secretion | 2 | 2.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 7 | 1.0 |
Epitopes/analysis | 3 | 1.0 |
Abnormalities, Multiple/*genetics/pathology | 2 | 2.0 |
Myelin Sheath/*physiology/ultrastructure | 3 | 60.0 |
Glutathione Transferase/genetics | 4 | 1.0 |
Protein Kinases/*metabolism | 4 | 1.0 |
Signal Transduction/*physiology | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 4 | 0.0 |
Cytotoxicity Tests, Immunologic | 8 | 1.0 |
*Immunodominant Epitopes | 2 | 22.0 |
Myelin Basic Proteins/chemistry/*immunology/metabolism | 2 | 100.0 |
Antigen-Presenting Cells/*metabolism | 2 | 20.0 |
B-Lymphocytes | 2 | 1.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Cyclopentanes/pharmacology | 2 | 4.0 |
Antigens, Surface/immunology | 5 | 2.0 |
Egtazic Acid/pharmacology | 2 | 1.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Blood Proteins/*physiology | 5 | 20.0 |
Cytoplasmic Granules/metabolism | 2 | 5.0 |
Glial Fibrillary Acidic Protein/analysis | 13 | 8.0 |
Autoimmune Diseases/*immunology | 7 | 4.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Brain/enzymology | 7 | 3.0 |
Methylation | 3 | 0.0 |
*Antibody Specificity | 3 | 4.0 |
Ribonucleoproteins/*immunology | 2 | 15.0 |
Multiple Sclerosis/*immunology/pathology | 3 | 25.0 |
Cerebrospinal Fluid/*metabolism | 2 | 33.0 |
Dementia/*metabolism | 2 | 11.0 |
Neurons/metabolism | 2 | 0.0 |
Calcium/pharmacology | 6 | 2.0 |
Carbohydrate Sequence | 3 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Immunoglobulin M/analysis | 4 | 1.0 |
*Aging | 2 | 1.0 |
Fetus/metabolism | 3 | 1.0 |
HLA-DR4 Antigen/*genetics | 2 | 6.0 |
Antibodies, Viral/analysis | 2 | 1.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
Carrier Proteins/immunology | 5 | 13.0 |
HIV-1/*immunology | 3 | 0.0 |
Immunoglobulin G/analysis | 8 | 2.0 |
Fibroblasts/enzymology | 2 | 1.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Anions | 2 | 4.0 |
Cations | 3 | 3.0 |
Particle Size | 2 | 0.0 |
Phosphatidylcholines | 2 | 5.0 |
Blood Pressure/*drug effects | 4 | 2.0 |
Acute-Phase Proteins/genetics | 2 | 28.0 |
Mannose | 2 | 25.0 |
Binding Sites, Antibody | 7 | 2.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Erythrocytes/drug effects | 2 | 9.0 |
Hemolysis | 2 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Multiple Sclerosis/*metabolism | 10 | 50.0 |
Sequence Homology, Nucleic Acid | 15 | 0.0 |
Amino Acids/metabolism | 2 | 2.0 |
Myelin Basic Proteins/chemical synthesis/*immunology | 3 | 100.0 |
Peptides/chemical synthesis/immunology | 5 | 11.0 |
Glasgow Coma Scale | 2 | 7.0 |
Phosphopyruvate Hydratase/*cerebrospinal fluid | 4 | 66.0 |
*Chromosome Mapping | 4 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
*Genetics, Population | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 3 | 2.0 |
Lipids/analysis | 2 | 4.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Trypsin/metabolism | 3 | 2.0 |
Pregnancy Trimester, Second | 3 | 1.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Heat-Shock Proteins/genetics/*immunology | 2 | 66.0 |
Ions | 2 | 2.0 |
Histocompatibility Antigens Class II/genetics/immunology | 2 | 10.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Double-Blind Method | 4 | 0.0 |
Myelin Proteins/*metabolism | 4 | 20.0 |
Schwann Cells/*pathology | 2 | 22.0 |
Mice, Mutant Strains | 5 | 0.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Antibodies/analysis | 4 | 3.0 |
DNA Probes | 7 | 0.0 |
Chimeric Proteins/genetics/immunology | 2 | 14.0 |
Autoimmune Diseases/blood/*immunology/pathology | 2 | 66.0 |
CD4-Positive T-Lymphocytes/*immunology | 8 | 1.0 |
Multiple Sclerosis/blood/*immunology/pathology | 2 | 66.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 3 | 5.0 |
Cell Division/physiology | 2 | 0.0 |
Multigene Family | 3 | 0.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
Interferon Type II/biosynthesis | 6 | 1.0 |
Interleukin-4/biosynthesis | 2 | 1.0 |
*Myelin Proteolipid Protein | 3 | 60.0 |
*Multigene Family | 2 | 0.0 |
DNA, Complementary/analysis/genetics | 2 | 2.0 |
Multiple Sclerosis/immunology/therapy | 2 | 66.0 |
Carbohydrates/pharmacology | 2 | 18.0 |
Phospholipids/*metabolism | 2 | 1.0 |
Molecular Mimicry | 2 | 2.0 |
*Immunization, Passive | 3 | 5.0 |
Lymph Nodes/cytology/immunology | 3 | 12.0 |
Transfection/immunology | 2 | 4.0 |
Cell Degranulation | 6 | 14.0 |
Eosinophils/pathology | 2 | 5.0 |
Pancreatic Elastase/analysis | 2 | 11.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Epidermal Growth Factor/*pharmacology | 3 | 0.0 |
Protein Kinase C/antagonists & inhibitors/*physiology | 2 | 7.0 |
Oligodendroglia/metabolism/pathology | 2 | 28.0 |
Randomized Controlled Trials | 2 | 0.0 |
Myelin Proteins/chemistry/metabolism | 2 | 100.0 |
Peripheral Nervous System Diseases/*immunology | 2 | 13.0 |
Central Nervous System/*physiology | 3 | 18.0 |
Gene Expression/physiology | 3 | 0.0 |
Interferon Type II/*genetics | 3 | 5.0 |
Apoproteins/*pharmacology | 2 | 50.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Transferrin/*pharmacology | 2 | 15.0 |
Antigens, CD/metabolism | 3 | 0.0 |
Antigens, Differentiation, Myelomonocytic/metabolism | 3 | 1.0 |
Carbonic Anhydrases/metabolism | 2 | 14.0 |
Cell Count/methods | 2 | 3.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Greenland/ethnology | 2 | 100.0 |
Inuits/genetics | 2 | 50.0 |
DNA/*genetics | 5 | 1.0 |
Karyotyping | 6 | 0.0 |
Gene Therapy | 2 | 0.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
Leukocyte Adherence Inhibition Test | 3 | 25.0 |
Threonine/metabolism | 2 | 2.0 |
Glycoproteins/immunology | 2 | 2.0 |
Proteolipids/*immunology | 3 | 100.0 |
Recombinant Fusion Proteins/biosynthesis/pharmacology | 2 | 40.0 |
Multiple Sclerosis | 3 | 75.0 |
DNA Primers/chemistry | 2 | 0.0 |
Immunoglobulin Idiotypes | 2 | 22.0 |
Hydrolases/metabolism | 2 | 14.0 |
Isoelectric Point | 2 | 1.0 |
Interleukin-5/*pharmacology | 2 | 6.0 |
Fetal Blood/chemistry | 2 | 3.0 |
*Gene Frequency | 2 | 0.0 |
Chemical Fractionation | 3 | 4.0 |
Insulin-Like Growth Factor I/*pharmacology | 2 | 1.0 |
Myelin Proteins/*biosynthesis/genetics | 2 | 66.0 |
*Immunization | 3 | 6.0 |
Mice, Inbred CBA | 2 | 0.0 |
Microscopy | 2 | 7.0 |
Recombinant Fusion Proteins/isolation & purification | 2 | 40.0 |
Multiple Sclerosis/*etiology | 2 | 50.0 |
T-Lymphocytes | 2 | 0.0 |
Codon | 2 | 0.0 |
Complement 3/*metabolism | 2 | 1.0 |
Complement Activation/*drug effects | 4 | 4.0 |
Hydrolysis/drug effects | 2 | 8.0 |
Lectins/*immunology | 2 | 7.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
Autoantibodies/cerebrospinal fluid | 2 | 100.0 |
Acylation | 3 | 4.0 |
Mannose/metabolism | 4 | 13.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Immunologic Deficiency Syndromes/blood/*genetics | 2 | 100.0 |
Brain/immunology | 7 | 26.0 |
*Genes, MHC Class II | 2 | 0.0 |
Complement 1q/metabolism | 3 | 12.0 |
Phagocytosis | 4 | 1.0 |
Myeloproliferative Disorders/*genetics/pathology | 2 | 33.0 |
Adenosine Triphosphate/metabolism | 4 | 0.0 |
Inuits | 2 | 33.0 |
Chromatography, Ion Exchange | 10 | 3.0 |
Myelin Basic Proteins/isolation & purification/metabolism | 2 | 100.0 |
Amino Acids/analysis | 7 | 2.0 |
Oligodeoxyribonucleotides | 12 | 1.0 |
Nerve Tissue Proteins/genetics | 2 | 0.0 |
Neurologic Examination | 5 | 4.0 |
Histamine Release/*drug effects | 2 | 6.0 |
Leukotriene C4/biosynthesis | 2 | 25.0 |
*Genes | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Cricetulus | 2 | 0.0 |
Leukemia, Erythroblastic, Acute/pathology | 2 | 6.0 |
Carrier Proteins/chemistry/metabolism | 2 | 6.0 |
Monocytes/metabolism | 3 | 0.0 |
HLA-DQ Antigens/immunology | 3 | 7.0 |
HLA-DR Antigens/immunology | 6 | 2.0 |
Bronchoalveolar Lavage Fluid/cytology | 2 | 1.0 |
DNA/metabolism | 2 | 0.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Histocompatibility Antigens Class II/*metabolism | 2 | 3.0 |
Myelin P2 Protein | 4 | 57.0 |
Receptors, Cholinergic/immunology | 4 | 22.0 |
Multiple Sclerosis/drug therapy | 2 | 40.0 |
Recombinant Fusion Proteins/biosynthesis/chemistry/metabolism | 2 | 8.0 |
Spinal Cord/*metabolism | 2 | 6.0 |
*Epitopes | 6 | 4.0 |
Apoptosis/*immunology | 2 | 1.0 |
Myelin Basic Proteins/*blood | 7 | 100.0 |
Nervous System Diseases/*immunology | 5 | 31.0 |
Myelin Basic Proteins/blood/*immunology | 2 | 100.0 |
Phosphoprotein Phosphatase/*antagonists & inhibitors | 2 | 12.0 |
Protein Kinase C/antagonists & inhibitors | 3 | 2.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
Ribosomal Protein S6 Kinases | 2 | 8.0 |
Tyrosine/metabolism | 2 | 0.0 |
Opsonins/blood | 3 | 50.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Eosinophil Peroxidase | 5 | 8.0 |
Neurotoxins/analysis | 3 | 100.0 |
Complement 3/metabolism | 3 | 1.0 |
Complement Pathway, Classical | 3 | 2.0 |
Models, Structural | 2 | 1.0 |
Myelin Basic Proteins/chemistry/immunology | 2 | 100.0 |
Clinical Trials | 3 | 0.0 |
Cell Adhesion | 6 | 0.0 |
Histocompatibility Antigens Class II/immunology | 5 | 2.0 |
T-Lymphocytes, Cytotoxic/*immunology | 11 | 2.0 |
Cell Membrane/immunology | 4 | 1.0 |
Drug Carriers | 2 | 1.0 |
Interleukin-2/biosynthesis | 3 | 0.0 |
Monocytes/*immunology | 2 | 0.0 |
Nervous System Diseases/immunology | 7 | 77.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Interleukin-10/*biosynthesis | 2 | 3.0 |
Oligonucleotide Probes | 3 | 0.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Cyclic AMP/pharmacology | 2 | 1.0 |
Endopeptidases/*metabolism | 3 | 2.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 4 | 14.0 |
Major Histocompatibility Complex | 6 | 2.0 |
Immune Sera/immunology | 7 | 4.0 |
Complement Activation/*immunology | 2 | 3.0 |
Cross Reactions/immunology | 3 | 6.0 |
Complement/*physiology | 2 | 2.0 |
Glioma/*metabolism | 2 | 4.0 |
Lectins/*metabolism | 3 | 5.0 |
Immunochemistry | 7 | 3.0 |
*Brain Chemistry | 9 | 5.0 |
HLA-D Antigens/immunology | 2 | 5.0 |
Myelin Basic Proteins/*immunology/isolation & purification | 2 | 100.0 |
Optic Neuritis/*immunology | 4 | 100.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Acetylglucosamine/pharmacology | 2 | 20.0 |
Herpesvirus 2, Human/*immunology | 2 | 20.0 |
Autoantibodies/*biosynthesis | 2 | 3.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Transplantation, Autologous | 2 | 0.0 |
Demyelinating Diseases/*pathology | 3 | 75.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Demyelinating Diseases/etiology | 2 | 50.0 |
Peptide Hydrolases/metabolism | 3 | 2.0 |
Immunologic Techniques | 6 | 1.0 |
*Myelin-Associated Glycoprotein | 2 | 16.0 |
Conserved Sequence | 2 | 0.0 |
RNA Splicing | 3 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/genetics/immunology | 2 | 22.0 |
DNA/*analysis | 3 | 1.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Sheep/*genetics | 2 | 3.0 |
Evolution | 2 | 0.0 |
Mice, Neurologic Mutants/*genetics | 2 | 18.0 |
Lymphocytes/*metabolism | 3 | 1.0 |
*Transcription, Genetic | 7 | 0.0 |
Paraparesis, Tropical Spastic/*immunology | 2 | 28.0 |
Nervous System/*immunology | 2 | 40.0 |
Thyroxine/blood | 2 | 0.0 |
Antibody Specificity/*immunology | 2 | 7.0 |
Epitopes/*analysis | 6 | 3.0 |
Myelin Proteolipid Protein | 22 | 91.0 |
*Antigens, Surface | 2 | 2.0 |
*Blood Proteins | 2 | 2.0 |
Mast Cells/drug effects | 2 | 22.0 |
Bone Marrow Cells | 2 | 0.0 |
Lectins/*blood | 3 | 50.0 |
Mannose/*blood | 2 | 66.0 |
Immunoglobulin G/*cerebrospinal fluid | 7 | 58.0 |
Immunoglobulins/cerebrospinal fluid | 2 | 66.0 |
Neuropsychological Tests | 2 | 0.0 |
Spinal Cord/pathology/physiopathology | 2 | 66.0 |
Antigens, CD14 | 2 | 0.0 |
Interleukin-1/biosynthesis | 2 | 1.0 |
Xenopus laevis | 2 | 0.0 |
Carrier Proteins/biosynthesis | 2 | 3.0 |
Biological Assay | 3 | 1.0 |
Autoantibodies/analysis | 3 | 1.0 |
Encephalomyelitis, Autoimmune, Experimental/immunology/*physiopathology | 2 | 100.0 |
Myelin Proteins/*physiology | 2 | 40.0 |
Proteolipids/metabolism | 2 | 8.0 |
*Antigens, CD44 | 2 | 9.0 |
Phagocytosis/*physiology | 2 | 4.0 |
Complement/metabolism | 2 | 2.0 |
Liver/*chemistry | 3 | 8.0 |
Antibodies/*immunology | 8 | 6.0 |
Cerebrospinal Fluid/immunology | 2 | 28.0 |
Multiple Sclerosis/*blood/*cerebrospinal fluid/immunology | 2 | 66.0 |
HLA-D Antigens/*immunology | 3 | 5.0 |
Myelin Basic Proteins/cerebrospinal fluid/*immunology | 2 | 100.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Epithelial Cells | 2 | 0.0 |
Myelin-Associated Glycoprotein | 18 | 14.0 |
Immunoglobulin G/*analysis | 3 | 4.0 |
Interleukin-4/*genetics | 2 | 4.0 |
Myasthenia Gravis/*genetics/immunology | 3 | 25.0 |
Myelin Proteins/immunology | 6 | 23.0 |
Central Nervous System/*chemistry | 2 | 33.0 |
Lipids/chemistry | 2 | 8.0 |
Astrocytes/metabolism | 2 | 2.0 |
Myelin Proteins/biosynthesis/genetics | 2 | 33.0 |
Peanut Agglutinin | 3 | 10.0 |
Plant Lectins | 2 | 4.0 |
Spinal Cord/cytology/*embryology | 2 | 40.0 |
Antibodies, Anti-Idiotypic/*immunology | 2 | 4.0 |
Immunoglobulin Idiotypes/immunology | 2 | 8.0 |
Biological Markers/cerebrospinal fluid | 3 | 11.0 |
HLA-DQ Antigens/genetics | 3 | 1.0 |
Lod Score | 2 | 0.0 |
Myelin Basic Proteins/isolation & purification/*metabolism | 2 | 50.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Complement Activation/*physiology | 2 | 8.0 |
Lectins/*physiology | 2 | 25.0 |
Monocytes/immunology | 4 | 1.0 |
Brain/blood supply | 2 | 5.0 |
Endothelium, Vascular/*immunology | 2 | 2.0 |
Immunoglobulin G/biosynthesis | 3 | 1.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Stereoisomerism | 2 | 0.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Rabbits/immunology | 6 | 6.0 |
Complement 1q/*metabolism | 2 | 10.0 |
Monocytes/physiology | 3 | 2.0 |
Proteolipids/chemistry/metabolism | 2 | 100.0 |
Labor, Obstetric/blood | 3 | 23.0 |
HLA Antigens/immunology | 4 | 2.0 |
Chemotaxis, Leukocyte/*physiology | 2 | 6.0 |
Neutrophils/immunology | 2 | 1.0 |
Lipids/chemistry/metabolism | 2 | 14.0 |
Myelin Sheath/immunology/metabolism | 2 | 100.0 |
Complementarity Determining Regions/immunology | 2 | 66.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
*Chromosomes, Human, Pair 18 | 4 | 2.0 |
Lymph Nodes/cytology | 2 | 4.0 |
Macrophages/*physiology | 2 | 2.0 |
Oligodeoxyribonucleotides/chemistry | 5 | 2.0 |
*CCAAT-Enhancer-Binding Proteins | 3 | 2.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
Intracranial Pressure | 2 | 25.0 |
Gene Expression/drug effects | 2 | 0.0 |
Neutrophils/*enzymology | 2 | 1.0 |
*DNA | 3 | 9.0 |
Linkage (Genetics)/*genetics | 2 | 0.0 |
Multiple Sclerosis/diagnosis/epidemiology/*genetics | 2 | 66.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine | 2 | 3.0 |
Alkaloids/pharmacology | 2 | 1.0 |
Ethers, Cyclic/*pharmacology | 2 | 16.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
Okadaic Acid | 2 | 4.0 |
Piperazines/pharmacology | 2 | 1.0 |
Staurosporine | 2 | 2.0 |
Brain/*enzymology | 4 | 2.0 |
Brain/growth & development/*metabolism | 3 | 11.0 |
Heparin/pharmacology | 3 | 1.0 |
*Adhesins, Bacterial | 2 | 11.0 |
Molecular Structure | 2 | 0.0 |
Catalysis | 2 | 0.0 |
Spinal Cord/immunology | 2 | 28.0 |
Cerebrospinal Fluid/*immunology | 2 | 40.0 |
Encephalomyelitis, Autoimmune, Experimental/immunology/pathology | 2 | 66.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Russia | 2 | 2.0 |
T-Lymphocytes/*immunology/physiology | 2 | 5.0 |
DNA/*genetics/isolation & purification | 2 | 3.0 |
Sharks | 5 | 26.0 |
Recombinant Proteins/isolation & purification/metabolism | 2 | 1.0 |
Carrier Proteins/*chemistry/immunology | 2 | 100.0 |
Eosinophils/*immunology | 3 | 5.0 |
S100 Proteins/*analysis | 2 | 4.0 |
Trachea/drug effects | 2 | 50.0 |
Disability Evaluation | 2 | 5.0 |
Predictive Value of Tests | 3 | 0.0 |
Prednisone/*therapeutic use | 2 | 7.0 |
Eosinophilia/*blood | 2 | 50.0 |
Eosinophils/*chemistry | 2 | 25.0 |
Injections, Intraperitoneal | 3 | 2.0 |
Autoantibodies/*analysis | 6 | 2.0 |
Synaptophysin/analysis | 2 | 5.0 |
Vimentin/analysis | 3 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase | 2 | 5.0 |
Insulin/*pharmacology | 2 | 0.0 |
Protein Kinases/isolation & purification/*metabolism | 3 | 15.0 |
Cerebral Cortex/pathology | 2 | 4.0 |
Tuberous Sclerosis/*pathology | 2 | 28.0 |
Alzheimer Disease/metabolism | 2 | 3.0 |
Hypersensitivity, Delayed | 3 | 4.0 |
DNA | 4 | 0.0 |
Nervous System Diseases/*cerebrospinal fluid | 4 | 50.0 |
Eosinophils/*metabolism | 4 | 12.0 |
Pregnancy, Animal/*blood | 2 | 33.0 |
Cerebrospinal Fluid/cytology/immunology | 2 | 20.0 |
Hybrid Cells | 3 | 0.0 |
Rats/*genetics | 2 | 3.0 |
Immunoglobulin Idiotypes/*immunology | 3 | 7.0 |
Immunoglobulin Isotypes | 2 | 12.0 |
Immunoglobulin M/biosynthesis | 2 | 2.0 |
*Peptide Fragments | 2 | 14.0 |
Superoxides/*metabolism | 2 | 2.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Demyelinating Diseases/*cerebrospinal fluid | 2 | 66.0 |
Neoplasms/*immunology | 3 | 2.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Myelin Basic Proteins/*biosynthesis | 2 | 66.0 |
Antigens, CD57 | 4 | 6.0 |
Myelin Proteins/metabolism | 3 | 33.0 |
Contrast Media | 2 | 3.0 |
Fibroblast Growth Factors/pharmacology | 2 | 3.0 |
Microtubule-Associated Proteins/metabolism | 3 | 2.0 |
Multiple Sclerosis/*blood | 2 | 18.0 |
*Embryonic and Fetal Development | 3 | 2.0 |
*Evolution | 2 | 1.0 |
Myelin P0 Protein | 4 | 22.0 |
*Biological Markers | 2 | 1.0 |
Membrane Glycoproteins/immunology | 2 | 1.0 |
Protein-Arginine N-Methyltransferase/*metabolism | 2 | 40.0 |
Central Nervous System/*pathology | 2 | 15.0 |
Myelin Basic Proteins/chemistry/metabolism | 2 | 100.0 |
*Variation (Genetics) | 2 | 0.0 |
Neurotoxins/pharmacology | 2 | 9.0 |
Trachea/*drug effects | 2 | 66.0 |
Histones/immunology | 2 | 33.0 |
Measles virus/*immunology | 2 | 16.0 |
Mumps virus/immunology | 2 | 33.0 |
Antigens, Differentiation/analysis | 3 | 0.0 |
Fibronectins/analysis | 2 | 3.0 |
Rats, Inbred Strains | 8 | 1.0 |
Antibodies/*analysis | 5 | 4.0 |
Gangliosides/immunology | 3 | 27.0 |
Skin Tests | 2 | 1.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
CA-15-3 Antigen | 2 | 2.0 |
Mice, Inbred ICR | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Antibodies/*cerebrospinal fluid | 5 | 45.0 |
Multiple Sclerosis/etiology/*immunology | 2 | 100.0 |
Isoelectric Focusing | 3 | 0.0 |
Multiple Sclerosis/*cerebrospinal fluid | 6 | 37.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
Muscle Contraction/*drug effects | 2 | 8.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
Software | 2 | 0.0 |
Myelin Basic Proteins/*isolation & purification | 4 | 100.0 |
Antibody-Producing Cells/immunology | 2 | 8.0 |
Myelin Proteins/analysis | 6 | 66.0 |
Myelin Sheath/*analysis | 3 | 60.0 |
Oligodendroglia/analysis | 2 | 40.0 |
Cathepsin D | 2 | 66.0 |
Receptors, Antigen, T-Cell, alpha-beta | 3 | 8.0 |
Deoxyribonuclease I | 2 | 1.0 |
Myelin Basic Proteins/*biosynthesis/genetics/immunology | 2 | 100.0 |
Peptides/*therapeutic use | 2 | 16.0 |
Evoked Potentials, Visual | 2 | 9.0 |
Intermediate Filament Proteins/analysis | 3 | 7.0 |
Blood Coagulation Factors/immunology | 2 | 40.0 |
Macrophages/immunology | 3 | 1.0 |
DNA/analysis | 3 | 0.0 |
Complement Pathway, Alternative/*drug effects | 2 | 9.0 |
Antigens, Differentiation, T-Lymphocyte | 5 | 1.0 |
Polysaccharides, Bacterial/metabolism | 2 | 22.0 |
*Myelin Basic Proteins | 5 | 100.0 |
2',3'-Cyclic-Nucleotide Phosphodiesterases/metabolism | 3 | 33.0 |
Measles virus/immunology | 4 | 33.0 |
Antigens, Surface/analysis | 3 | 0.0 |
Nerve Tissue Proteins/immunology | 2 | 20.0 |
Phosphatidylglycerols/metabolism | 2 | 40.0 |
Dose-Response Relationship, Immunologic | 8 | 1.0 |
*Immunologic Techniques | 2 | 6.0 |
*Leukocyte Adherence Inhibition Test | 2 | 50.0 |
Immunosorbent Techniques | 2 | 0.0 |
Myelin Sheath/*enzymology | 3 | 42.0 |
Oligopeptides/chemical synthesis/immunology | 2 | 20.0 |
Nervous System Diseases/cerebrospinal fluid | 4 | 44.0 |
Autoradiography | 2 | 0.0 |
Mice, Jimpy | 2 | 66.0 |
*Phosphoric Diester Hydrolases | 4 | 15.0 |
Alkylation | 2 | 2.0 |
Complement Pathway, Classical/*drug effects | 2 | 11.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Myelin Sheath/analysis | 2 | 40.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Membrane Potentials/drug effects | 2 | 1.0 |
Neurofilament Proteins | 3 | 13.0 |
Phosphopyruvate Hydratase/metabolism | 2 | 3.0 |
Spinal Cord/*embryology/metabolism | 2 | 50.0 |
Cerebrosides/immunology | 2 | 66.0 |
Lymphocytes/*immunology | 4 | 0.0 |
Multiple Sclerosis/*diagnosis/immunology | 2 | 66.0 |
Neuroglia/*immunology | 3 | 23.0 |
Oligodendroglia/*immunology | 2 | 18.0 |
T-Lymphocytes/classification/*immunology | 2 | 3.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Myelin Basic Proteins/*analysis/immunology | 4 | 100.0 |
Phosphotransferases/*metabolism | 2 | 5.0 |
Italy | 2 | 0.0 |
Central Nervous System Diseases/immunology | 2 | 33.0 |
Brain Diseases/cerebrospinal fluid | 2 | 66.0 |
Cross-Sectional Studies | 2 | 0.0 |
Multiple Sclerosis/*cerebrospinal fluid/immunology | 2 | 28.0 |
Encephalomyelitis, Autoimmune, Experimental/*etiology/pathology | 3 | 75.0 |
Demyelinating Diseases/*cerebrospinal fluid/diagnosis | 2 | 100.0 |
Multiple Sclerosis/cerebrospinal fluid/diagnosis | 2 | 66.0 |
Myelin Basic Proteins/analysis/*cerebrospinal fluid | 2 | 100.0 |
Chemistry | 2 | 0.0 |
Multiple Sclerosis/enzymology | 2 | 50.0 |
Leukocytes, Mononuclear/drug effects/*metabolism | 2 | 5.0 |
Glial Fibrillary Acidic Protein/*analysis | 3 | 6.0 |
Phosphopyruvate Hydratase/*analysis | 2 | 10.0 |
Polyradiculoneuropathy/cerebrospinal fluid | 2 | 100.0 |
Immunoglobulin G/biosynthesis/cerebrospinal fluid | 2 | 66.0 |
Rosette Formation | 3 | 0.0 |
Radioimmunoassay/methods | 7 | 4.0 |
Antibody Formation/*immunology | 2 | 15.0 |
Cell Fractionation | 3 | 1.0 |
*Polyomaviridae | 2 | 40.0 |
Central Nervous System/pathology | 2 | 9.0 |
Polyradiculoneuropathy/*immunology | 2 | 28.0 |
Astrocytes/immunology | 2 | 33.0 |
*Myelin Sheath | 2 | 66.0 |
Brain | 2 | 5.0 |
Myelin Basic Proteins/immunology/*isolation & purification | 2 | 100.0 |
Cytoplasmic Granules/analysis | 2 | 28.0 |
Cerebrovascular Disorders/immunology | 3 | 75.0 |
2',3'-Cyclic-Nucleotide Phosphodiesterases/*analysis | 2 | 100.0 |
Phosphoric Diester Hydrolases/*analysis | 2 | 66.0 |
Antigen-Antibody Complex/*analysis | 2 | 1.0 |
Antibodies, Monoclonal/*analysis | 2 | 4.0 |
Subacute Sclerosing Panencephalitis/*immunology | 2 | 50.0 |
Glial Fibrillary Acidic Protein | 3 | 15.0 |
Autistic Disorder/*immunology | 2 | 50.0 |
*Antibody-Dependent Cell Cytotoxicity | 2 | 4.0 |
*Antigen-Antibody Complex | 2 | 3.0 |
Measles/immunology | 2 | 28.0 |
Feasibility Studies | 2 | 0.0 |
Myelin Basic Proteins/*blood/*cerebrospinal fluid | 2 | 100.0 |
